Enanta Pharm (NASDAQ: ENTA) reported Q3 EPS of $2.61, $0.94 better than the analyst estimate of $1.67. Revenue for the quarter came in at $42.1 million versus the consensus estimate of $40.83 million.

For earnings history and earnings-related data on Enanta Pharm (ENTA) click here.